Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSpyre Therapeutics board member Peter Harwin resigns; annual meeting approves ESPP amendment
Filed May 29, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
medium
Board member Peter Harwin resigned effective May 27, 2026, reducing board size from eight to seven directors. Company states resignation was not due to any disagreement on operations, policies, or practices.
Item 5.02 verify on EDGAR → -
low
Stockholders approved amended 2016 Employee Stock Purchase Plan with 66.9M votes for versus 45.5K against, representing strong support for employee benefit program.
Item 5.07 verify on EDGAR → -
low
Three Class I directors elected to three-year terms through 2029: Mark McKenna, Cameron Turtle, and Laurie Stelzer, all receiving majority shareholder support.
Item 5.07 verify on EDGAR → -
low
Executive compensation approved on advisory basis with 93% shareholder support (62.1M for vs 4.8M against), indicating satisfaction with pay practices.
Item 5.07 verify on EDGAR → -
low
KPMG LLP ratified as independent auditor for 2026 with overwhelming approval (68.4M votes for), showing no shareholder concerns about auditor relationship.
Item 5.07 verify on EDGAR →
Summary
Spyre Therapeutics reported results from its May 27, 2026 annual meeting, where stockholders approved routine governance matters including an amended employee stock purchase plan and the re-election of three directors. The most notable development was the resignation of board member Peter Harwin, which reduced the board from eight to seven members.
The company emphasized this was an amicable departure with no disagreements on company operations or strategy. For retail investors, the annual meeting results suggest stable governance with strong shareholder support across all proposals. The 93% approval rate for executive compensation and overwhelming auditor ratification indicate no significant shareholder concerns.
The board reduction is modest and appears to be a planned transition rather than a crisis departure. Watch for the company's proxy statement or subsequent disclosures that may provide details on what changes were made to the Employee Stock Purchase Plan, as the 8-K filing itself provides no specifics on the amendments that stockholders approved.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
8-K filing appears incomplete or truncated with no substantive disclosure provided.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As discussed in
The 8-K filing references Item 5.02, which typically covers officer or director departures, appointments, or compensation changes. However, the text cuts off mid-sentence ('As discussed in') with no substantive information provided. This appears to be an incomplete or corrupted filing.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Spyre held annual meeting approving ESPP amendment and electing directors; board member Peter Harwin resigned with no disagreement.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s stockholders elected three Class I directors, Mark McKenna, Cameron Turtle, and Laurie Stelzer, each to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
Three Class I directors were elected to serve three-year terms until 2029: Mark McKenna (65.6M votes), Cameron Turtle (66.2M votes), and Laurie Stelzer (57.0M votes). All three received majority support from voting shareholders.
Event · Item 9.01 — Financial Statements and Exhibits
Spyre Therapeutics filed an amended and restated 2016 Employee Stock Purchase Plan with no material business impact disclosed.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
10.1 Spyre Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan
The company filed an amended and restated version of its 2016 Employee Stock Purchase Plan as an exhibit. The 8-K provides no details about what changes were made to the plan or their impact on employees or shareholders.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify